

**Report prepared by**

Robert A. Angel

Jason Grago

Sarah C. Dean

Lixin Qu

Kathryn S. Carrier

Robert A. Hummer

Eric A. Whitsel

Wave VI Survey Medications Use User Guide



CAROLINA POPULATION CENTER | CAROLINA SQUARE - SUITE 210 | 123 WEST FRANKLIN STREET | CHAPEL HILL, NC 27516

Add Health is supported by grant U01 AG071448 (Hummer) and grant U01 AG071450 (Aiello and Hummer) from the National Institute of Aging at NIH, with cooperative funding from 4 other federal agencies and foundations.

This document summarizes the medication inventory conducted during the Wave VI survey. It also documents the protocol for assigning therapeutic classes to those medications. Whenever possible, the inventory and protocol in the Wave VI survey and at the home exam mirrored those of Wave V to ensure comparability of data within and between waves.

Acknowledgment

Data for Wave VI of Add Health were supported by two cooperative agreements from the National Institute on Aging (1U01AG071448, principal investigator Robert A. Hummer, and 1U01AG071450, principal investigators Robert A. Hummer and Allison E. Aiello) to the University of North Carolina at Chapel Hill. Co-funding for Wave VI was provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Institute on Minority Health and Health Disparities, the National Institute on Drug Abuse, the NIH Office of Behavioral and Social Science Research, and the NIH Office of Disease Prevention. Data from Waves I-V of Add Health are from the Add Health Program Project, grant P01 HD31921 (Kathleen Mullan Harris) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, with cooperative funding from 23 other federal agencies and foundations. Add Health was originally designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the University of North Carolina at Chapel Hill. Add Health is currently directed by Robert A. Hummer; it was previously directed by Kathleen Mullan Harris (2004-2021) and J. Richard Udry (1994-2004). Information on obtaining Add Health data are available on the project website (<https://addhealth.cpc.unc.edu>).

Suggested Citation

Angel RA, Grago J, Dean, SC, Qu L, Carrier KS, Hummer RA, Whitsel EA. Add Health Wave VI Documentation: Medication Use – Add Health Survey, 2025; Available from <http://www.cpc.unc.edu/projects/addhealth/documentation/guides/> or <https://doi.org/10.17615/kvxf-5r56>

Table of Contents

Suggested Citation	2
1. Introduction	4
2. Collection of Prescription Medication Use Data	4
3. Therapeutic Classification of Prescription Medications (H6SSET1 – H6SSET4)	6
4. Key Therapeutic Classes of Prescription Medications	6
4.1 Antihypertensive Medication Use (H6SAHT)	7
4.2 Antihyperlipidemic Medication Use (H6SCMED2)	7
4.3 Antidiabetic Medication Use (H6SCMED)	8
4.4 Anti-Inflammatory Medication Use (H6SCR2 – H6SCR8)	8
4.5 Narcotic Medication Use (H6SNARC)	9
4.6 Antidepressant Medication Use (H6SADX, where X is defined by the last 3 letters of the variable name)	10
4.7 Antipsychotic Medication Use (H6SAPS)	10
4.8 Anxiolytic, Sedative or Hypnotic Medication Use (H6SASH)	11
4.9 Anticonvulsant Medication Use (H6SACO)	11
4.10 Anorexiant and Antiobesity Medication Use (H6SAOA)	12
4.11 Antiparkinson and Alzheimer’s Disease Medication Use (H6SPKALZ)	13
5. Quality Control of the Prescription Medication Data	13
6. The Medication Data File (svymeds6)	13
6.1 Hierarchical Structure	13
6.2 Participant-Level Overview of Medication Use	14
6.3 The Variables	14
7. References	15

1. Introduction

Data on participant use of prescription medications were collected during the Wave VI survey. The collection procedure varied by sample / mode (Sample 1 web or in-person; Sample 2 in-person), which are described in Section 2 and fully detailed in the Wave VI documentation.¹ The process for collecting the prescription medication data, therapeutically classifying the prescription medications, and structuring a file of the therapeutic classifications for dissemination to users is described below. Please note that data on select over-the-counter (aspirin-containing and non-steroidal anti-inflammatory) medications were not collected in the Wave VI survey. These data were only collected during the Wave VI home exam.

2. Collection of Prescription Medication Use Data

Prescription medication data were provided by participants during the web and in-person surveys. Participants who completed a web or in-person survey were asked to provide the names of all prescription medications used within the past four weeks. As medication names were typed on the screen (either by participants or interviewers), a look-up list of medications with identical or similar names was displayed on the screen. The look-up list was based on a medication information and classification database (Multum LexiconTM, Cerner Multum, Inc.; Denver, CO) created by excerpting all generic and brand names included in the most current quarterly update. The survey instruments were updated with new medication lists on a quarterly basis throughout the data collection period.

During the web survey, participants were instructed to select the correct medication name from the list. If the correct medication name did not appear on the screen, they were instructed to select the option “Name not on list”, continue to the next screen, and then manually type the full name of the correct medication into a free-text data entry field. During the in-person survey, interviewers selected the correct medication name from the list. If the correct medication name did not appear on the screen, they manually typed the full name of the correct medication into a free-text data entry field. The web and in-person instruments were programmed to accommodate up to thirty medications per participant.

Web participants also self-reported whether they entered medication names from medication containers or from memory. In-person interviewers recorded whether participants provided medication containers or named medications from memory.

The questions which appeared in each mode are listed below:

H6ID9

We want to record all prescription medications that you have used in the past four weeks. These medications include solid and non-solid formulations that you may swallow, inhale, apply to the skin or hair, inject, implant, or place in the ears, eyes, nose, mouth, or any other part of the body.

[If the participant reported their biological sex as female, then the following was added.]

This also includes prescription birth control and any birth control implants such as Implanon or Nexplanon and intrauterine devices, or IUDs.

Have you taken any prescription medications in the past four weeks?

1=Yes

2=No

H6ID10

The next questions are about medications you have taken in the past 4 weeks. If you can get your medication bottles now, having those will make it easier for you to enter the name of the medication.

Did you get your bottles or containers for the medications you have taken in the past 4 weeks?

1=Yes

2=No

3=I have some of my bottles or containers, but not all

[The following MED269 questions looped through for up to 30 medications.]

MED269

What is the name of the medication?

Begin typing medication name. Select the medication name from the look up list. If you cannot find name, type "NAME NOT ON LIST" and select that option from the look up list.

MED269_oth

If MED269=NAME NOT ON LIST or text does not match dropdown list, then:

Type in the medication name:

MED269_container

[The following question was asked in the In-Person Interview only]

Interviewer: Did participant present this medication or its container during the interview?

1=Yes

2=No

3. Therapeutic Classification of Prescription Medications (H6SSET1 – H6SSET4)

In 2019, a contract allowing for therapeutic classification of the prescription medications in the look-up list using an updated version of the Multum Lexicon™ (Cerner Multum, Inc.; Denver, CO) was executed. Of the 18,902 prescription medications reported by participants, 37 (< 1%) could not be automatically assigned to a therapeutic class using this database. A general internist and cardiovascular epidemiologist with expertise in medication classification manually assigned therapeutic classes to 20 of the 37 prescription medications using two on-line coding databases (Merative™ Micromedex®; Merative; Ann Arbor, Michigan; www.micromedexsolutions.com and Facts And Comparisons®; Wolters Kluwer; Alphen aan den Rijn, Netherlands; www.wolterskluwer.com). The Wave VI medication file therefore contains the therapeutic class for 18,885 prescription medications (Appendix 1).

In the data file, the nine-digit therapeutic classification codes associated with each prescription medication include a hierarchical series of up to three, three-digit codes representing, from left to right, the (general) therapeutic class, the (more specific) therapeutic subclass, and (most specific) therapeutic subgroup. For example, a prescription medication coded 001-009-161 is in the anti-infective class, cephalosporins subclass, and third generation cephalosporins subgroup. A prescription medication coded 001-018-*** is in the anti-infective class and aminoglycosides subclass. In other words, three, right-sided asterisks (***) in the nine-digit code indicate that subgrouping was impossible and six (***_***) indicate that both subclassification and subgrouping were impossible. A prescription medication coded 998-998-998 indicates that classification of the medication was impossible. A prescription medication coded 999-999-999 indicates that the participant reported taking prescription medication(s), but the specific medication(s) was not reported by the participant. Lastly, a prescription medication coded 996-996-996 indicates that the participant refused to report their medication(s).

Because the study did not collect indications for treatment and some prescription medications are used on- or off-label to treat a variety of conditions, each prescription medication may be associated with up to four unique, nine-digit therapeutic classification codes, i.e. Sets 1-4.

4. Key Therapeutic Classes of Prescription Medications

Use of a prescription medication in the past 4 weeks in one or more of the listed therapeutic classes was assigned a value of 1. Non-use of a prescription medication in the past four weeks in one of the listed therapeutic classes was assigned a value of 0. Therapeutically classified use of prescription medication in particular classes may confound biomarker-based estimates of disease prevalence or risk. For example, use of anti-hypertensive medications may confound blood pressure-based estimates of hypertension

prevalence or cardiovascular disease risk. However, the following (1,0) classifications should be used cautiously in the investigation or control of potential confounding, because selection biases often threaten the study of non-randomized medication exposures.^{2,3}

4.1 Antihypertensive Medication Use (H6SAHT)

Participants used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic classes:

Class	Label	Variable
040-042-***	Angiotensin converting enzyme (ACE) inhibitors	H6SAHT
040-043-***	Anti-adrenergic agents (peripherally acting)	
040-044-***	Anti-adrenergic agents (centrally acting)	
040-046-386	Beta-adrenergic blocking agents	
040-047-***		
040-046-388	Calcium channel blocking agents	
040-048-***		
040-049-156	Thiazide diuretics	
040-053-***	Vasodilators	
040-055-***	Antihypertensive Combinations	
040-056-***	Angiotensin II (AT2) inhibitors	
040-342-***	Renin inhibitors	
040-482-***	Angiotensin receptor blocker and neprilysin inhibitors	

4.2 Antihyperlipidemic Medication Use (H6SCMED2)

Participants used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic classes:

Class	Label	Variable
358-019-***	Antihyperlipidemic agents	H6SCMED2
358-019-173	HMG-CoA reductase inhibitors	
358-019-174	Miscellaneous antihyperlipidemic agents	
358-019-241	Fibric acid derivatives	
358-019-252	Bile acid sequestrants	
358-019-316	Cholesterol absorption inhibitors	
358-019-317	Antihyperlipidemic combinations	
358-019-484	PCSK9 inhibitors	

4.3 Antidiabetic Medication Use (H6SCMED)

Participants used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic classes:

Class	Label	Variable
358-099-***	Antidiabetic agents	H6SCMED
358-099-213	Sulfonylureas	
358-099-214	Non-sulfonylureas	
358-099-215	Insulin	
358-099-216	Alpha-glucosidase inhibitors	
358-099-271	Thiazolidinediones	
358-099-282	Meglitinides	
358-099-309	Miscellaneous antidiabetic agents	
358-099-314	Antidiabetic combinations	
358-099-371	Dipeptidyl peptidase 4 inhibitors	
358-099-372	Amylin analogs	
358-099-373	Incretin mimetics	
358-099-458	SGLT-2 inhibitors	

4.4 Anti-Inflammatory Medication Use (H6SCR2 – H6SCR8)

Participants used ≥ 1 medication identified by ≥ 1 of the following questions, coded therapeutic classes, or active ingredients (listed below):

Question / Class	Label	Variable
057-058-061	NSAIDs past 4 weeks or	H6SCR2
057-058-062	Salicylate past 4 weeks or Any oral medication that contains NSAID or Salicylate as an active ingredient in a combination medication past 4 weeks	
057-058-278	Cyclooxygenase-2 (COX-2) Inhibitor past 4 weeks	
122-130-296	Inhaled Corticosteroids past 4 weeks	
097-098-300	Corticotropin or	H6SCR5
097-098-301	Glucocorticoid past 4 weeks	
105-192-***	Antirheumatic or	H6SCR6
105-270-***	Antipsoriatic past 4 weeks	

254-104-***	Immunosuppressive agents	H6SCR7
Any of the above	Any of the above anti-inflammatories	H6SCR8

Active Ingredients:

NSAIDS

- Bromfenac
- Diclofenac
- Diflunisal
- Etodolac
- Fenoprofen
- Flurbiprofen
- Ibuprofen
- Indomethacin
- Ketoprofen
- Ketorolac
- Meclofenamate
- Mefenamic Acid
- Meloxicam
- Nabumetone
- Naproxen
- Oxaprozin
- Piroxicam
- Sulindac
- Tolmetin

Salicylates

- Aspirin
- Choline salicylate
- Magnesium salicylate
- Salsalate
- Sodium salicylate
- Thiosalicylate

4.5 Narcotic Medication Use (H6SNARC)

Participants used ≥ 1 opioid-containing prescription medication in ≥ 1 of the following coded therapeutic classes:

Class	Label	Variable
057-058-060	Narcotic analgesics	H6SNARC
057-058-191	Narcotic analgesic combinations	
057-073-179	Skeletal muscle relaxant combinations	
122-124-***	Antitussives	
122-132-***	Upper respiratory combinations	

--and--

the prescription medication contained ≥ 1 of the following active ingredients:

- Alfentanil
- Codeine
- Fentanyl
- Buprenorphine
- Dezocine
- Hydrocodone
- Butorphanol
- Dihydrocodeine
- Hydromorphone

- Levomethadyl
- Methadone
- Oliceridine
- Oxymorphone
- Remifentanil
- Tramadol
- Levorphanol
- Morphine
- Opium
- Pentazocine
- Sufentanil
- Meperidine
- Nalbuphine
- Oxycodone
- Propoxyphene
- Tapentadol

4.6 Antidepressant Medication Use (H6SADX, where X is defined below by the last 3 letters of the variable name)

Participants used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic classes:

Class	Label	Variable
242-079-***	Psychotherapeutic combinations†	H6SADCMB
242-249-076	Miscellaneous antidepressants	H6SADMSC
242-249-208	Selective serotonin reuptake inhibitors	H6SADSRI
242-249-209	Tricyclic antidepressants	H6SADTRI
242-249-250	Monoamine oxidase inhibitors	H6SADMOI
242-249-306	Phenylpiperazine antidepressants	H6SADPHE
242-249-307	Tetracyclic antidepressants	H6SADTET
242-249-308	Selective serotonin norepinephrine reuptake inhibitors	H6SADSNR
Any of the above	Any of the above antidepressants	H6SADANY

†Excluding the following medications:

- Cobenfy
- Lybalvi
- Olanzapine-Samidorphan
- Trospium-Xanomeline

4.7 Antipsychotic Medication Use (H6SAPS)

Participants used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic classes:

Class	Label	Variable
242-079-***	Psychotherapeutic combinations†	H6SAPS
242-251-***	Antipsychotic agents	
242-251-077	Miscellaneous antipsychotic agents	
242-251-210	Phenothiazine antipsychotics	
242-251-280	Thioxanthenes	
242-251-341	Atypical antipsychotics	

†Excluding the following medications:

- Amitriptyline-Chlordiazepoxide
- Limbitrol

4.8 Anxiolytic, Sedative or Hypnotic Medication Use (H6SASH)

Participants used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic classes:

Class	Label	Variable
057-067-***	Anxiolytic, sedative and hypnotic agents	H6SASH
057-067-068	Barbiturates	
057-067-069	Benzodiazepines	
057-067-070	Miscellaneous anxiolytics, sedatives and hypnotics	

4.9 Anticonvulsant Medication Use (H6SACO)

Participants used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic classes:

Class	Label	Variable
057-064-***	Anticonvulsant agents	H6SACO
057-064-199	Hydantoin anticonvulsants	
057-064-200	Succinimide anticonvulsants	
057-064-201	Barbiturate anticonvulsants	
057-064-202	Oxazolidinedione anticonvulsants	
057-064-203	Benzodiazepine anticonvulsants	
057-064-204	Miscellaneous anticonvulsants	
057-064-311	Dibenzazepine anticonvulsants	

057-064-345	Fatty acid derivative anticonvulsants	
057-064-346	Gamma-aminobutyric acid reuptake inhibitors	
057-064-347	Gamma-aminobutyric acid analogs	
057-064-348	Triazine anticonvulsants	
057-064-349	Carbamate anticonvulsants	
057-064-350	Pyrrolidine anticonvulsants	
057-064-351	Carbonic anhydrase inhibitor anticonvulsants	
057-064-352	Urea anticonvulsants	
057-064-446	Neuronal potassium channel openers	
057-064-456	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists	

4.10 Anorexiant and Antiobesity Medication Use (H6SAOA)

Participants used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic classes:

Class	Label	Variable
057-253-***	Anorexiant	H6SAOA
358-099-214	Biguanides	
358-099-373	GLP-1 receptor agonists	
358-099-458	SGLT-2 inhibitors	
358-359-***	Peripherally acting antiobesity agents	
	Any medication that contains one of the following biguanides, GLP-1 receptor agonists or SGLT-2 inhibitors as an active ingredient	

Active Ingredients:

Biguanides

- Metformin

GLP-1 Receptor Agonists

- Albiglutide
- Liraglutide
- Tirzepatide
- Dulaglutide
- Lixisenatide
- Exenatide
- Semaglutide

SGLT-2 Inhibitors

- Bexagliflozin
- Empagliflozin
- Canagliflozin
- Ertugliflozin
- Dapagliflozin
- Sotagliflozin

4.11 Antiparkinson and Alzheimer's Disease Medication Use (H6SPKALZ)

Participants used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic classes:

Class	Label	Variable
057-066-***	Antiparkinson agents	H6SPKALZ
057-066-205	Anticholinergic antiparkinson agents (excluding medications containing diphenhydramine as the sole anticholinergic antiparkinson agent as an active ingredient)	
057-066-206	Miscellaneous antiparkinson agents	
057-066-276	Dopaminergic antiparkinsonism agents	
057-080-***	Miscellaneous central nervous system agents (containing an ergoloid mesylate, glutamate receptor antagonist, or amyloid-targeting monoclonal antibody as an active ingredient)	
057-313-***	Cholinesterase inhibitors	

Active Ingredients:

- Ergoloid mesylates
- Memantine
- Aducanumab
- Lecanemab
- Donanemab

5. Quality Control of the Prescription Medication Data

Of the 11,979 Add Health participants who completed the Wave VI survey, 6,073 also completed a home exam. Among 5,985 (98.6%) of them, prescription medication use was inventoried twice (during the Wave VI survey *and* home exam), albeit using somewhat different methods administered on average (95% confidence interval [CI]) 4.4 (4.3, 4.5) months apart. Nonetheless, the agreement (95% CI) between therapeutic classifications was 66% (65%-67%) and kappa coefficient (95% CI) was 0.70 (0.68-0.72). The observations suggest that within Add Health Wave VI, prescription medication data are comparable across the survey and home exam.

6. The Medication Data File (svymeds6)

6.1 Hierarchical Structure

The structure of the disseminated medication data file is hierarchical. This means that it is a medication-level data file, where each therapeutically classified prescription medication appears in the data as a single

observation. Therefore, if a participant reported taking more than one medication, the participant identifier (AID variable) will appear in the data file more than once. Alternatively, the participant identifier will appear in the data file just one time on a single observation if: (a) the participant reported using just one medication, (b) the participant reported not taking any medications, (c) the participant refused to answer the specific medication question, (d) the participant skipped reporting their medications, or (e) the participant was not asked the prescription medication question.

6.2 Participant-Level Overview of Medication Use

Given the complex hierarchical structure of the data file, this section provides an overview, **at the participant-level**, of the medications reported by the participants:

Of the 11,979 participants who participated in the survey, 6,498 (54.2%) took prescription medications, 5,279 (44.1%) took no medications, and 202 (1.7%) skipped the prescription medication question.

Of the 6,498 participants who took prescription medications, 6,178 (95.1%) took from 1 to 30 prescription medications, and 320 (4.9%) did not report their prescription medications.

6.3 The Variables

The medication data file includes the variables below, which are described in the corresponding codebook documentation that also contains frequencies. Please note, however, that the frequencies reported in the codebook are at the medication-level and **not** at the participant-level.

<u>Variable Name</u>	<u>Variable Label</u>
AID	Participant Identifier
H6ID9	Take Any Prescription Medication in the past 4 weeks (S4Q37)
H6SSET1 – H6SSET4	Therapeutic Classification – Set #1 – #4
H6SAHT	Antihypertensive
H6SCMED2	Antihyperlipidemic
H6SCMED	Antidiabetic
H6SCR2	CRP - NSAID/salicylate (4 weeks)
H6SCR3	CRP - Cox-2 inhibitor
H6SCR4	CRP - Inhaled corticosteroid
H6SCR5	CRP - Corticotropin/Glucocorticoid
H6SCR6	CRP - Antirheumatic/Antipsoriatic
H6SCR7	CRP - Immunosuppressive
H6SCR8	Anti-Inflammatory
H6SNARC	Narcotic
H6SADCMB	AD - Psychotherapeutic combinations
H6SADMSC	AD - Miscellaneous
H6SADSRI	AD - Selective serotonin reuptake inhibitors

H6SADTRI	AD - Tricyclic
H6SADMOI	AD - Monoamine oxidase inhibitors
H6SADPHE	AD - Phenylpiperazine
H6SADTET	AD - Tetracyclic
H6SADSNR	AD - Selective serotonin norepinephrine reuptake inhibitors
H6SADANY	Antidepressant
H6SAPS	Antipsychotic
H6SASH	Anxiolytic/Sedative/Hypnotic
H6SACO	Anticonvulsant
H6SAOA	Anorexiant/Antiobesity agent
H6SPKALZ	Antiparkinson/Alzheimer's disease
H6STMEDS	# of Prescription Medications inventoried

Given all of the former complexities, Add Health users possessing no to little prior experience working with medication data are strongly advised to collaborate with a health care professional familiar with the challenges and pitfalls associated with doing so.

7. References

1. Hummer RA, Dean SC, Liao D, Cooney D, Jackson C, Griffiths A, Aiello AE. 2025. Wave VI Sampling and Mixed-Mode Survey Design. Chapel Hill, NC: Carolina Population Center, University of North Carolina at Chapel Hill.
2. Sendor R, Stürmer T. Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators. *Pharmacoepidemiol Drug Saf* 2022;31(3):261-269.
3. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *Am J Epidemiol* 2003;158(9):915-920.

Appendix 1

Table. Therapeutic Classification Codes	
Code	Name
001	anti-infectives
002	amebicides
003	anthelmintics
004	antifungals
005	antimalarial agents
006	antituberculosis agents
007	antiviral agents
008	carbapenems
009	cephalosporins
010	leprostatics
011	macrolide derivatives
012	miscellaneous antibiotics
013	penicillins
014	quinolones
015	sulfonamides
016	tetracyclines
017	urinary anti-infectives
018	aminoglycosides
019	antihyperlipidemic agents
020	antineoplastics
021	alkylating agents
022	antineoplastic antibiotics
023	antimetabolites
024	antineoplastic hormones
025	miscellaneous antineoplastics
026	mitotic inhibitors
027	radiopharmaceuticals
028	biologicals
030	antitoxins and antivenins
031	bacterial vaccines
032	colony stimulating factors
033	immune globulins
034	in vivo diagnostic biologicals
036	erythropoiesis-stimulating agents
038	viral vaccines
040	cardiovascular agents
041	agents for hypertensive emergencies
042	angiotensin converting enzyme (ACE) inhibitors
043	antiadrenergic agents, peripherally acting
044	antiadrenergic agents, centrally acting
045	antianginal agents

Table. Therapeutic Classification Codes	
Code	Name
046	antiarrhythmic agents
047	beta-adrenergic blocking agents
048	calcium channel blocking agents
049	diuretics
050	inotropic agents
051	miscellaneous cardiovascular agents
052	peripheral vasodilators
053	vasodilators
054	vasopressors
055	antihypertensive combinations
056	angiotensin II inhibitors
057	central nervous system agents
058	analgesics
059	miscellaneous analgesics
060	narcotic analgesics
061	nonsteroidal anti-inflammatory agents
062	salicylates
063	analgesic combinations
064	anticonvulsants
065	antiemetic/antivertigo agents
066	antiparkinson agents
067	anxiolytics, sedatives, and hypnotics
068	barbiturates
069	benzodiazepines
070	miscellaneous anxiolytics, sedatives and hypnotics
071	CNS stimulants
072	general anesthetics
073	muscle relaxants
074	neuromuscular blocking agents
076	miscellaneous antidepressants
077	miscellaneous antipsychotic agents
079	psychotherapeutic combinations
080	miscellaneous central nervous system agents
081	coagulation modifiers
082	anticoagulants
083	antiplatelet agents
084	heparin antagonists
085	miscellaneous coagulation modifiers
086	thrombolytics
087	gastrointestinal agents
088	antacids
089	anticholinergics/antispasmodics
090	antidiarrheals
091	digestive enzymes

Table. Therapeutic Classification Codes	
Code	Name
092	gallstone solubilizing agents
093	GI stimulants
094	H2 antagonists
095	laxatives
096	miscellaneous GI agents
097	hormones/hormone modifiers
098	adrenal cortical steroids
099	antidiabetic agents
100	miscellaneous hormones
101	sex hormones
102	contraceptives
103	thyroid hormones
104	immunosuppressive agents
105	miscellaneous agents
106	antidotes
107	chelating agents
108	cholinergic muscle stimulants
109	local injectable anesthetics
110	miscellaneous uncategorized agents
111	psoralens
112	radiocontrast agents
113	genitourinary tract agents
115	nutritional products
116	iron products
117	minerals and electrolytes
118	oral nutritional supplements
119	vitamins
120	vitamin and mineral combinations
121	intravenous nutritional products
122	respiratory agents
123	antihistamines
124	antitussives
125	bronchodilators
126	methylxanthines
127	decongestants
128	expectorants
129	miscellaneous respiratory agents
130	respiratory inhalant products
131	antiasthmatic combinations
132	upper respiratory combinations
133	topical agents
134	anorectal preparations
135	antiseptic and germicides
136	dermatological agents

Table. Therapeutic Classification Codes	
Code	Name
137	topical anti-infectives
138	topical steroids
139	topical anesthetics
140	miscellaneous topical agents
141	topical steroids with anti-infectives
143	topical acne agents
144	topical antipsoriatics
146	mouth and throat products
147	ophthalmic preparations
148	otic preparations
149	spermicides
150	sterile irrigating solutions
151	vaginal preparations
153	plasma expanders
154	loop diuretics
155	potassium-sparing diuretics
156	thiazide and thiazide-like diuretics
157	carbonic anhydrase inhibitors
158	miscellaneous diuretics
159	first generation cephalosporins
160	second generation cephalosporins
161	third generation cephalosporins
162	fourth generation cephalosporins
163	ophthalmic anti-infectives
164	ophthalmic glaucoma agents
165	ophthalmic steroids
166	ophthalmic steroids with anti-infectives
167	ophthalmic anti-inflammatory agents
168	ophthalmic lubricants and irrigations
169	miscellaneous ophthalmic agents
170	otic anti-infectives
171	otic steroids with anti-infectives
172	miscellaneous otic agents
173	HMG-CoA reductase inhibitors (statins)
174	miscellaneous antihyperlipidemic agents
175	protease inhibitors
176	NRTIs
177	miscellaneous antivirals
178	skeletal muscle relaxants
179	skeletal muscle relaxant combinations
180	adrenergic bronchodilators
181	bronchodilator combinations
182	androgens and anabolic steroids
183	estrogens

Table. Therapeutic Classification Codes	
Code	Name
184	gonadotropins
185	progestins
186	sex hormone combinations
187	miscellaneous sex hormones
191	narcotic analgesic combinations
192	antirheumatics
193	antimigraine agents
194	antigout agents
195	5HT3 receptor antagonists
196	phenothiazine antiemetics
197	anticholinergic antiemetics
198	miscellaneous antiemetics
199	hydantoin anticonvulsants
200	succinimide anticonvulsants
201	barbiturate anticonvulsants
202	oxazolidinedione anticonvulsants
203	benzodiazepine anticonvulsants
204	miscellaneous anticonvulsants
205	anticholinergic antiparkinson agents
206	miscellaneous antiparkinson agents
208	SSRI antidepressants
209	tricyclic antidepressants
210	phenothiazine antipsychotics
211	platelet aggregation inhibitors
212	glycoprotein platelet inhibitors
213	sulfonylureas
214	biguanides
215	insulin
216	alpha-glucosidase inhibitors
217	bisphosphonates
218	alternative medicines
219	nutraceutical products
220	herbal products
222	penicillinase resistant penicillins
223	antipseudomonal penicillins
224	aminopenicillins
225	penicillins/beta-lactamase inhibitors
226	natural penicillins
227	NNRTIs
228	adamantane antivirals
229	purine nucleosides
230	aminosalicylates
231	thiocarbamide derivatives
232	rifamycin derivatives

Table. Therapeutic Classification Codes	
Code	Name
233	streptomyces derivatives
234	miscellaneous antituberculosis agents
235	polyenes
236	azole antifungals
237	miscellaneous antifungals
238	antimalarial quinolines
239	miscellaneous antimalarials
240	lincomycin derivatives
241	fibric acid derivatives
242	psychotherapeutic agents
243	leukotriene modifiers
244	nasal lubricants and irrigations
245	nasal steroids
246	nasal antihistamines and decongestants
247	nasal preparations
248	topical emollients
249	antidepressants
250	monoamine oxidase inhibitors
251	antipsychotics
252	bile acid sequestrants
253	anorexiant
254	immunologic agents
256	interferons
261	heparins
262	coumarins and indanediones
263	erectile dysfunction agents
264	urinary antispasmodics
265	urinary pH modifiers
266	miscellaneous genitourinary tract agents
267	ophthalmic antihistamines and decongestants
268	vaginal anti-infectives
269	miscellaneous vaginal agents
270	antipsoriatics
271	thiazolidinediones
272	proton pump inhibitors
273	lung surfactants
274	beta blockers, cardioselective
275	beta blockers, non-cardioselective
276	dopaminergic antiparkinsonism agents
277	5-aminosalicylates
278	cox-2 inhibitors
279	gonadotropin-releasing hormone and analogs
280	thioxanthenes
281	neuraminidase inhibitors

Table. Therapeutic Classification Codes	
Code	Name
282	meglitinides
283	thrombin inhibitors
284	viscosupplementation agents
285	factor Xa inhibitors
286	mydriatics
287	ophthalmic anesthetics
288	5-alpha-reductase inhibitors
289	antihyperuricemic agents
290	topical antibiotics
291	topical antivirals
292	topical antifungals
293	glucose elevating agents
295	growth hormones
296	inhaled corticosteroids
297	mucolytics
298	mast cell stabilizers
299	anticholinergic bronchodilators
300	corticotropin
301	glucocorticoids
302	mineralocorticoids
303	agents for pulmonary hypertension
304	macrolides
305	ketolides
306	phenylpiperazine antidepressants
307	tetracyclic antidepressants
308	SSNRI antidepressants
309	miscellaneous antidiabetic agents
310	echinocandins
311	dibenzazepine anticonvulsants
312	cholinergic agonists
313	cholinesterase inhibitors
314	antidiabetic combinations
315	glycylcyclines
316	cholesterol absorption inhibitors
317	antihyperlipidemic combinations
318	insulin-like growth factor
319	vasopressin antagonists
320	smoking cessation agents
321	ophthalmic diagnostic agents
322	ophthalmic surgical agents
324	antineoplastic interferons
325	sclerosing agents
327	antiviral combinations
328	antimalarial combinations

Table. Therapeutic Classification Codes	
Code	Name
329	antituberculosis combinations
330	antiviral interferons
332	radiologic adjuncts
333	miscellaneous iodinated contrast media
334	lymphatic staining agents
335	magnetic resonance imaging contrast media
336	non-iodinated contrast media
337	ultrasound contrast media
338	diagnostic radiopharmaceuticals
339	therapeutic radiopharmaceuticals
340	aldosterone receptor antagonists
341	atypical antipsychotics
342	renin inhibitors
345	fatty acid derivative anticonvulsants
346	gamma-aminobutyric acid reuptake inhibitors
347	gamma-aminobutyric acid analogs
348	triazine anticonvulsants
349	carbamate anticonvulsants
350	pyrrolidine anticonvulsants
351	carbonic anhydrase inhibitor anticonvulsants
352	urea anticonvulsants
353	anti-angiogenic ophthalmic agents
354	H. pylori eradication agents
355	functional bowel disorder agents
356	serotonergic neuroenteric modulators
357	growth hormone receptor blockers
358	metabolic agents
359	peripherally acting antiobesity agents
360	lysosomal enzymes
361	miscellaneous metabolic agents
362	chloride channel activators
363	probiotics
364	antiviral chemokine receptor antagonist
366	integrase strand transfer inhibitor
368	non-ionic iodinated contrast media
369	ionic iodinated contrast media
370	otic steroids
371	dipeptidyl peptidase 4 inhibitors
372	amylin analogs
373	GLP-1 receptor agonists
374	cardiac stressing agents
375	peripheral opioid receptor antagonists
376	radiologic conjugating agents
377	prolactin inhibitors

Table. Therapeutic Classification Codes	
Code	Name
378	drugs used in alcohol dependence
379	fifth generation cephalosporins
380	topical debriding agents
381	topical depigmenting agents
382	topical antihistamines
383	antineoplastic detoxifying agents
384	platelet-stimulating agents
385	group I antiarrhythmics
386	group II antiarrhythmics
387	group III antiarrhythmics
388	group IV antiarrhythmics
389	group V antiarrhythmics
390	hematopoietic stem cell mobilizer
392	otic anesthetics
393	cerumenolytics
394	topical astringents
395	topical keratolytics
397	multikinase inhibitors
398	BCR-ABL tyrosine kinase inhibitors
399	CD52 monoclonal antibodies
400	CD33 monoclonal antibodies
401	CD20 monoclonal antibodies
402	VEGF/VEGFR inhibitors
403	mTOR inhibitors
404	EGFR inhibitors
405	HER2 inhibitors
406	glycopeptide antibiotics
407	inhaled anti-infectives
408	histone deacetylase inhibitors
409	bone resorption inhibitors
410	adrenal corticosteroid inhibitors
411	calcitonin
412	uterotonic agents
413	antigonadotropic agents
414	antidiuretic hormones
415	miscellaneous bone resorption inhibitors
416	somatostatin and somatostatin analogs
417	selective estrogen receptor modulators
418	parathyroid hormone and analogs
419	gonadotropin-releasing hormone antagonists
420	antiandrogens
422	antithyroid agents
423	aromatase inhibitors
424	estrogen receptor antagonists

Table. Therapeutic Classification Codes	
Code	Name
426	synthetic ovulation stimulants
427	tocolytic agents
428	progesterone receptor modulators
430	anticholinergic chronotropic agents
431	anti-CTLA-4 monoclonal antibodies
432	vaccine combinations
433	catecholamines
435	selective phosphodiesterase-4 inhibitors
437	immunostimulants
438	interleukins
439	other immunostimulants
440	therapeutic vaccines
441	calcineurin inhibitors
442	TNF alpha inhibitors
443	interleukin inhibitors
444	selective immunosuppressants
445	other immunosuppressants
446	neuronal potassium channel openers
447	CD30 monoclonal antibodies
448	topical non-steroidal anti-inflammatories
449	hedgehog pathway inhibitors
450	topical antineoplastics
451	topical photochemotherapeutics
452	CFTR modulators
453	topical rubefacient
454	proteasome inhibitors
455	guanylate cyclase-C agonists
456	AMPA receptor antagonists
457	hydrazide derivatives
458	SGLT-2 inhibitors
459	urea cycle disorder agents
460	phosphate binders
461	topical anti-rosacea agents
462	allergenics
463	protease-activated receptor-1 antagonists
464	miscellaneous diagnostic dyes
465	diarylquinolines
467	ACE inhibitors with thiazides
468	antiadrenergic agents (central) with thiazides
469	antiadrenergic agents (peripheral) with thiazides
470	miscellaneous antihypertensive combinations
472	beta blockers with thiazides
473	angiotensin II inhibitors with thiazides
475	potassium sparing diuretics with thiazides

Table. Therapeutic Classification Codes	
Code	Name
476	ACE inhibitors with calcium channel blocking agents
479	angiotensin II inhibitors with calcium channel blockers
480	antiviral boosters
481	NK1 receptor antagonists
482	angiotensin receptor blockers and neprilysin inhibitors
484	PCSK9 inhibitors
485	NS5A inhibitors
486	oxazolidinone antibiotics
487	CFTR combinations
488	anticoagulant reversal agents
489	CD38 monoclonal antibodies
490	peripheral opioid receptor mixed agonists/antagonists
491	local injectable anesthetics with corticosteroids
492	cephalosporins/beta-lactamase inhibitors
493	anti-PD-1 monoclonal antibodies
494	PARP inhibitors
495	calcimimetics
496	VMAT2 inhibitors
497	cation exchange resins
498	antineoplastic combinations
499	carbapenems/beta-lactamase inhibitors
500	PI3K inhibitors
501	CDK 4/6 inhibitors
502	CGRP inhibitors
503	streptogramins
504	antimanic agents
505	transthyretin stabilizers
507	malignancy photosensitizers
508	NHE3 inhibitors
509	BTK inhibitors
510	miscellaneous erythropoiesis agents
512	melanocortin receptor agonists
514	hereditary angioedema agents
515	peripheral opioid receptor agonists
516	noradrenergic uptake inhibitors for ADHD
517	CD19 monoclonal antibodies
518	other cephalosporins
519	alpha-adrenoreceptor antagonists
520	bispecific antibodies
521	bispecific T-cell engagers (BiTE)
522	miscellaneous bispecific antibodies
523	monobactams
526	antiviral monoclonal antibodies

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein may not be specific to your market, country, or population, is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist. Copyright 1996-2025 Cerner Multum, Inc.